Targeting CD19: the good, the bad, and CD81
- PMID: 28057672
- PMCID: PMC5216268
- DOI: 10.1182/blood-2016-11-749143
Targeting CD19: the good, the bad, and CD81
Abstract
In this issue of Blood,
Conflict of interest statement
Conflict-of-interest disclosure: The Center for Cell and Gene Therapy at Baylor College of Medicine had a research collaboration with Celgene and Bluebird Bio, and currently has research collaborations with Cell Medica and Tessa Therapeutics. M.P.V. and S.G. have patents and/or patent applications in the fields of T-cell therapy and/or oncolytics.
Figures

Comment on
-
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.Blood. 2017 Jan 5;129(1):100-104. doi: 10.1182/blood-2016-05-718395. Epub 2016 Oct 26. Blood. 2017. PMID: 27784674
Similar articles
-
The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment.J Immunol. 2003 Oct 15;171(8):4062-72. doi: 10.4049/jimmunol.171.8.4062. J Immunol. 2003. PMID: 14530327
-
The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts.J Immunol. 2004 Jan 1;172(1):370-80. doi: 10.4049/jimmunol.172.1.370. J Immunol. 2004. PMID: 14688345
-
Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection.J Viral Hepat. 2003 Jan;10(1):10-5. doi: 10.1046/j.1365-2893.2003.00380.x. J Viral Hepat. 2003. PMID: 12558906
-
Receptor modulators of B-cell receptor signalling--CD19/CD22.Curr Top Microbiol Immunol. 2000;245(1):195-212. doi: 10.1007/978-3-642-57066-7_6. Curr Top Microbiol Immunol. 2000. PMID: 10533314 Review. No abstract available.
-
Development of human lymphohematopoiesis defined by CD34 and CD81 expression.Leuk Lymphoma. 2002 Dec;43(12):2269-73. doi: 10.1080/1042819021000039974. Leuk Lymphoma. 2002. PMID: 12613512 Review.
Cited by
-
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells.Cancer Cell. 2021 Dec 13;39(12):1610-1622.e9. doi: 10.1016/j.ccell.2021.09.011. Epub 2021 Oct 21. Cancer Cell. 2021. PMID: 34678150 Free PMC article.
-
Blinatumomab in Ph+ B-ALL: present and perspectives.Oncotarget. 2017 Oct 25;8(55):93309-93310. doi: 10.18632/oncotarget.22071. eCollection 2017 Nov 7. Oncotarget. 2017. PMID: 29212147 Free PMC article. No abstract available.
-
Open conformation of tetraspanins shapes interaction partner networks on cell membranes.EMBO J. 2020 Sep 15;39(18):e105246. doi: 10.15252/embj.2020105246. Epub 2020 Aug 16. EMBO J. 2020. PMID: 32974937 Free PMC article.
-
Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.Iran J Basic Med Sci. 2018 May;21(5):455-464. doi: 10.22038/IJBMS.2018.26778.6557. Iran J Basic Med Sci. 2018. PMID: 29922424 Free PMC article.
-
Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases.Cancers (Basel). 2023 Apr 6;15(7):2186. doi: 10.3390/cancers15072186. Cancers (Basel). 2023. PMID: 37046846 Free PMC article. Review.
References
-
- Braig F, Brandt A, Goebeler M, et al. . Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129(1):100-104. - PubMed
-
- May MB, Glode A. Blinatumomab: A novel, bispecific, T-cell engaging antibody. Am J Health Syst Pharm. 2016;73(1):e6-e13. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials